Interferon beta-1b vs Rebif (interferon beta 1a)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline

Interferon beta-1b

Marketed by Bayer

Approved in Multiple Sclerosisbiologic (interferon)
Partial signal

NCT00099502 · Phase 3 · completed

The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment); Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time (up to 60 months after start of treatment); Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60 (60 months after start of treatment): Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS (mixed)

Result source: NCT00185211

Rebif (interferon beta 1a)

Marketed by Merck KGaA and partners

Approved in Multiple Sclerosisbiologic (interferon)
Weak signal

NCT00110396 · Phase 3 · completed

The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.

Reported efficacy

Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Rebif New Formulation (RNF) Cohort 45 participants (not_applicable)

Result source: NCT00110396

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInterferon beta-1bRebif (interferon beta 1a)
Annualised relapse rate0.2 vs 0.3−0.1 vs placebon 292NCT00185211—Not posted · NCT00735007
Free of 3-month confirmed disability progression (%)—Not posted · NCT00099502—Not posted · NCT00735007
New or enlarging T2 lesions—Not posted · NCT00099502—Not posted · NCT00735007

Annualised relapse rate

Interferon beta-1b
0.2 vs 0.3−0.1 vs placebon 292NCT00185211
Rebif (interferon beta 1a)
—Not posted · NCT00735007

Free of 3-month confirmed disability progression (%)

Interferon beta-1b
—Not posted · NCT00099502
Rebif (interferon beta 1a)
—Not posted · NCT00735007

New or enlarging T2 lesions

Interferon beta-1b
—Not posted · NCT00099502
Rebif (interferon beta 1a)
—Not posted · NCT00735007
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Interferon beta-1b: 4 of 4 rows · Rebif (interferon beta 1a): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInterferon beta-1bRebif (interferon beta 1a)
Dropout rate
7.2%a
NCT00185211 · Phase 3 · monotherapy
show 1 more result
5.1%
NCT00370071 · Phase 3 · registry result, not featured evidence
13.8%b
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
—Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
13.8%
NCT00428584 · Phase 3 · registry result, not featured evidence
24.5%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
4.4%
NCT01071083 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%a
NCT00185211 · Phase 3 · monotherapy
show 1 more result
—
NCT00370071 · Phase 3 · registry result, not featured evidence
5.8%b
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
—Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
—
NCT00428584 · Phase 3 · registry result, not featured evidence
—
NCT02727907 · Phase 2/3 · registry result, not featured evidence
0%
NCT01071083 · Phase 2 · registry result, not featured evidence
Serious AEs
20.9%a
NCT00185211 · Phase 3 · monotherapy
show 1 more result
0%
NCT00370071 · Phase 3 · registry result, not featured evidence
5.8%b
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
8.5%Non-Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
5.3%Titrated
NCT00472797 · Phase 3 · registry result, not featured evidence
6.2%
NCT00428584 · Phase 3 · registry result, not featured evidence
0%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
—
NCT01071083 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
injection site reaction 55.8% (placebo 40.3%)
flu syndrome 52.1% (placebo 51.1%)
multiple sclerosis 38.4% (placebo 46.6%)
NCT00185211 · Phase 3 · monotherapy
show 1 more result
influenza like illness 41%
hepathic function abnormal 17.9%
headache 15.4%
NCT00370071 · Phase 3 · registry result, not featured evidence
b
influenza like illness 67.7%
headache 37.7%
injection site erythema 24.2%
NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3
show 5 more results
headache 32.2%
pain 16.9%
myalgia 11%
NCT00472797 · Phase 3 · registry result, not featured evidence
headache 24.8%
pain 14.2%
influenza-like illness 8%
NCT00472797 · Phase 3 · registry result, not featured evidence
general disorders and administration site condition 67.7%
infections and infestations 58.5%
nervous system disorders 44.6%
NCT00428584 · Phase 3 · registry result, not featured evidence
flu-like syndrom 28.3%
local reaction 28.3%
neutropenia 20.8%
NCT02727907 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 24.4% (placebo 11.9%)
headache 17.8% (placebo 7.1%)
dizziness 6.7% (placebo 0%)
NCT01071083 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Interferon beta-1b

Time to CDMS 26.9% (n=292) vs 45% (n=176) placebo @ 104wk
absolute value · percentage points
NCT00185211 · Phase 3 · monotherapy
show 2 more results
36.7% (n=292) vs 51.2% (n=176) placebo @ 156wk
NCT00185211 · Phase 3 · monotherapy
46.2% (n=292) vs 57.3% (n=176) placebo @ 260wk
NCT00185211 · Phase 3 · monotherapy
Time to EDSS Progression 12.8% (n=292) vs 19.9% (n=176) placebo @ 104wk
absolute value · percentage points
NCT00185211 · Phase 3 · monotherapy
show 2 more results
16.8% (n=292) vs 25.3% (n=176) placebo @ 156wk
NCT00185211 · Phase 3 · monotherapy
24.9% (n=292) vs 28.9% (n=176) placebo @ 260wk
NCT00185211 · Phase 3 · monotherapy
FAMS TOI 125 vs 125 placebo score @ 260wk
absolute value · score
NCT00185211 · Phase 3 · monotherapy
Time to MS McDonald 9.4 vs 6 placebo months
time to event · months
NCT00185211 · Phase 3 · monotherapy
Annualized Relapse 0.2139 vs 0.2695 placebo per year
event rate · per year
NCT00185211 · Phase 3 · monotherapy
MSFC Z 0.226 vs 0.225 placebo score @ 260wk
absolute value · score
NCT00185211 · Phase 3 · monotherapy
Newly Active Lesions 4 vs 7 placebo count @ 260wk
event count · count
NCT00185211 · Phase 3 · monotherapy
T2 Lesion Volume -123 vs -194.5 placebo mm @ 260wk
absolute change · mm
NCT00185211 · Phase 3 · monotherapy
Black Hole Volume 0 vs 0 placebo mm @ 260wk
absolute change · mm
NCT00185211 · Phase 3 · monotherapy
Brain Volume -2.281% (n=141) vs -1.771% (n=80) placebo @ 260wk
percent change · % of baseline
NCT00185211 · Phase 3 · monotherapy
New Active Lesion -1.5 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT00370071 · Phase 3 · registry result, not featured evidence
New Gd-Enhancing Lesions -0.5 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT00370071 · Phase 3 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

Rebif (interferon beta 1a)

Pain VAS 0.67 vs 1.14 Betaseron mm
absolute change · mm
Mean Change to 30 Minutes Post-Injection
NCT00428584 · Phase 3 · registry result, not featured evidence
Pain VAS 1.46 vs 4.63 Betaseron mm
absolute change · mm
NCT00428584 · Phase 3 · registry result, not featured evidence
show 1 more result
0.7 vs 1.89 Betaseron mm
NCT00428584 · Phase 3 · registry result, not featured evidence
Pain VAS 1.67 mm
absolute change · mm
Extension (open-label)
No placebo or comparator arm
NCT00428584 · Phase 3 · registry result, not featured evidence
show 2 more results
0.4 mm
NCT00428584 · Phase 3 · registry result, not featured evidence
0.34 mm
NCT00428584 · Phase 3 · registry result, not featured evidence
Newly Active Lesions 0 vs 0 Rebif lesions @ 52wk
event count · lesions
NCT02727907 · Phase 2/3 · registry result, not featured evidence
show 1 more result
0 vs 1 placebo lesions @ 16wk
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Annualized Relapse 0.113 relapses @ 52wk
event rate · relapses
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Relapse Free 92.5% (n=53) vs 88.2% (n=51) placebo @ 16wk
event count · % of participants
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to % from 49 Count of Participants as posted
show 1 more result
77.4% (n=53) vs 76.5% (n=51) placebo @ 52wk*
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to % from 41 Count of Participants as posted
Time to First Relapse 6.8 months @ 96wk
time to event · months
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 207 days as posted
Newly Active Lesions 0 lesions @ 96wk
event count · lesions
No placebo or comparator arm
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Annualized Relapse 0.208 vs 0.145 Rebif relapses @ 96wk
event rate · relapses
NCT02727907 · Phase 2/3 · registry result, not featured evidence
Time to First Relapse 1.1 vs 0.46 Rebif months @ 16wk
time to event · months
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 33.5 days as posted
show 1 more result
6.34 vs 4.06 Rebif months @ 52wk*
NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 193 days as posted
MRI and or Clinical Relapse Rescue 4.7% (n=45) vs 60.5% (n=41) placebo @ 28wk
absolute value · percentage points
NCT01071083 · Phase 2 · registry result, not featured evidence
MRI Activity Rescue 0% (n=45) vs 52.5% (n=41) placebo @ 28wk
absolute value · percentage points
NCT01071083 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · Rebif (interferon beta 1a)'s landscape